Corcept Therapeutics | CORT - 销售收入



金融业
股票价格
USD
资产
USD 814.88M
现金及等价物
USD 108.74M
销售成本
USD 2.88M
流动资产
USD 426.03M
流动负债
USD 149.19M
债务
USD 6.11M
EBIT
USD -49.6M
EBITDA
USD 4.2M
员工
500
EPS每股收益
USD -0.3
股本和储备
USD 637.99M
销售毛利
USD 162.02M
债务利息支出
USD 814.88M
利息收入
USD 5.42M
市值
USD 8.51B
净收入
USD -31.76M
营业费用
USD 214.5M
营业利润
USD -49.6M
普通股股本
USD 107.33M
PE价格收益
113.58
税前利润
USD 9.91M
销售收入
USD 164.9M
销售和管理费用
USD 128.04M
股票
USD 12.89M
贸易债权人
USD 33.31M
应收帐款人
USD 39.07M


销售 更改 日
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Alaunos Therapeutics USD 2K 2K 2025-03
ANI Pharmaceuticals USD 237.5M 9.56M 2026-03
Ardelyx USD 94.47M 30.74M 2026-03
Aurora Cannabis CAD 94.19M 3.82M 2025-12
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Canopy Growth CAD 71.25M 3.29M 2026-03
Corcept Therapeutics USD 164.9M 37.22M 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
J&J USD 24.1B 500M 2026-03
Knight Therapeutics CAD 133.11M 11.56M 2025-12
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Merck USD 16.29B 110M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Novartis USD 13.11B 226M 2026-03
Novartis USD 13.11B 750M 2026-03
Pacira USD 177M 19.87M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Supernus Pharmaceuticals USD 207.71M 3.89M 2026-03
TG Therapeutics USD 194.8M 2.23M 2026-03